NASDAQ : FDMT
4D Molecular Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 12.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 706.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 660.17M |
| Enterprise Value | 268.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 55.24M |
| Shares Outstanding | 55.24M |
| Shares Change (YoY) | +15.93% |
| Shares Change (QoQ) | +3.24% |
| Owned by Insiders (%) | 2.74% |
| Owned by Institutions (%) | 86.37% |
| Float | 42.55M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.15 |
| Forward PS | 43.91 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.03 |
| Quick Ratio | 7.68 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -43.25% |
| Return on Assets (ROA) | -25.09% |
| Return on Invested Capital (ROIC) | -27.21% |
| Return on Capital Employed (ROCE) | -43.58% |
| Weighted Average Cost of Capital (WACC) | 18.22% |
| Revenue Per Employee | $469,429 |
| Profits Per Employee | -$914,158 |
| Employee Count | 196 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.74 |
| 52-Week Price Change | +4.29% |
| 50-Day Moving Average | 13.72 |
| 200-Day Moving Average | 10.87 |
| Relative Strength Index (RSI) | 44.15 |
| Average Volume (20 Days) | 1,032,954 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.53M |
| Short Previous Month | 11.24M |
| Short % of Shares Out | 20.87% |
| Short % of Float | 27.10% |
| Short Ratio (days to cover) | 10.77 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 92.01M |
| Gross Profit | -145.10M |
| Operating Income | -193.92M |
| Pretax Income | -179.18M |
| Net Income | -179.18M |
| EBITDA | -188.89M |
| EBIT | -193.92M |
| Loss Per Share | -$2.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 361.33M |
| Total Debt | 39.22M |
| Net Cash | 391.41M |
| Net Cash Per Share | $7.09 |
| Equity (Book Value) | 407.66M |
| Book Value Per Share | 7.38 |
| Working Capital | 335.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -156.07M |
| Capital Expenditures | 106,000 |
| Depreciation & Amortization | 5.03M |
| Net Borrowing | 19.26M |
| Free Cash Flow | -155.97M |
| FCF Per Share | -$2.82 |
Margins
| Measure | Value |
|---|
| Gross Margin | -157.70% |
| Operating Margin | -210.76% |
| Pretax Margin | -194.74% |
| Profit Margin | -194.74% |
| EBITDA Margin | -205.30% |
| EBIT Margin | -210.76% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.93% |
| Shareholder Yield | -15.93% |
| Earnings Yield | -23.21% |
| FCF Yield | -23.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $28.09 |
| Price Target Difference | 135.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | -16.16% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.4 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |